Samsung Biologics (207940)

[Business Overview] Samsung Biologics is the world's largest contract development and manufacturing organization (CDMO) for biopharmaceuticals by aggregate fermentation capacity, operating four plants in Songdo, Incheon. The company is a strategic supplier to global biotech and pharma giants for monoclonal antibody and biosimilar production. Plant 5, ramping in 2025–2026, will lift total capacity past 780,000 liters. [Core Competitiveness] Samsung Biologics' moat is built on regulatory track record (FDA, EMA, MFDS facility approvals), the ability to scale 200,000-liter bioreactor lines, and the Samsung group's working-capital discipline. The CDMO industry's structural growth — driven by anti-obesity GLP-1 supply tightness, oncology biologics, and biosimilar uptake — favors capacity-rich, regulatory-credible operators. [Earnings Analysis] 2024–2025 saw consistent revenue growth as new contracts ramped at Plants 3 and 4. Operating margins remained among the highest in global CDMO, supported by long-duration contract structures. [Financial Health] Samsung Biologics is well capitalized, with the parent group supporting Plant 5 CapEx. The company's biosimilar subsidiary (Samsung Bioepis) recently completed transition to consolidated ownership, simplifying the corporate structure. [Outlook] GLP-1 manufacturing demand (Wegovy/Mounjaro class), oncology biologics pipeline, and Plant 5 ramp are the principal earnings drivers. Risks include FX, customer pricing pressure, and competitive Plant additions in China and India.